Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Also, I would say, our oncology business, which is comprised largely of independent oncology practices, continues to thrive |
| And just in summary, I would say that AmerisourceBergen as a purpose-driven company and future as Cencora is very well positioned for long-term growth, and we'll offer our shareholders a differentiated return |
| And our markets have been performing very well |
| In the second quarter, we delivered strong financial performance with revenue growth of nearly 10% and adjusted EPS growth of 9% |
| Literally, I'd say, and I try to be fairly modest then, but I am incredibly proud of the work that our companies do in World Courier, just foremost amongst that |
| And I think it adds hopefully to our reputation of solid execution and building on our strengths |
| This continued emphasis, along with the fundamental strength of our business and balance sheet, power our ability to continue investing internally and externally to drive our future growth |
| Our acquisitions that we've made recently continued to track very well |
| Every time I get on the phone with them, I'm so impressed with the dedication, the professionalism, the innovation mindset |
| And at the end of the day, if it's benefiting our constituencies, that will benefit AmerisourceBergen |
| And in parallel, AmerisourceBergen is executing and delivering strong performance |
| The fundamentals of our business remain strong, as we continue to capitalize on opportunities provided by our pharmaceutical-centric strategy and capabilities |
| Our results continue to demonstrate the value of our pharmaceutical-centric strategy key strategic partnerships, leadership in specialty and comprehensive global commercialization services |
| Our leadership in specialty distribution is a key differentiator for AmerisourceBergen, both with pharma manufacturers and with our downstream provider customers |
| And again, we think that overall, this is a benefit to patients |
| It's a tremendously strong second quarter for AB |
| And I think it's also part of the reason why Cencora is going to be a very good strategic name change for the company as we look to the quarters ahead |
| I'm proud of the way that our team has really embraced this acquisition |
| This investment will deepen and enhance our strong ties to community providers |
| And we are impressed with the quality of the teams and their positioning within the channels and are very interested in helping them grow and develop the business |
| So we're tremendously proud of the World Courier |
| The trusted relationships and legacy we have both within communities support our ultimate goal to create better patient experiences and outcomes across specialty classes and sites of care |
| I'll just say that we had very good operational performance internationally during the quarter |
| We're very proud of this acquisition |
| And so it's those sorts of things that are driving the continued good performance in the second half |
| We've really been able to enhance the team in the Health System segment of growing with market leaders |
| The ability to track and monitor the precise location of shipments in transit globally allows us to deliver superior service to our customers, proactively anticipate potential risks and ensure the secure and timely distribution of products |
| This capability further expands AmerisourceBergen's leadership in specialty logistics and positions us to be the partner of choice for innovative products in development and coming to market, such as cell and gene therapies that often require the ability to monitor temperature and location in real time |
| We also saw good results in our Animal Health business this most recent quarter |
| We're seeing utilization trends that continue to be strong |
| Statement |
|---|
| Consolidated gross profit margin was 3.71%, a decline of 13 basis points, due primarily to lower COVID treatment contributions and mix in the quarter |
| International Healthcare Solutions' operating income was $176 million, down approximately 6% on a reported basis, driven by a decline at Alliance Healthcare due to the effect of foreign currency exchange rates as well as the June 2022 divestiture of Profarma Specialty, which represented 3% of segment level operating income in the prior year quarter |
| I would say on 340B, we follow the market obviously, some of this historically had hurt some of our Part B car business as it went into health systems |
| I think a couple of years ago, we were lagging a bit in market share |
| In February, the earthquakes that impacted Turkey had a devastating humanitarian impact |
| This growth was moderated by a decline in sales of COVID-19 treatments versus the prior year quarter |
| As expected, our year-over-year operating expense growth rate slowed sequentially from the first quarter |
| In the quarter, International Healthcare Solutions revenue was $6.8 billion, down 0.2% on a reported basis or up 12% on a constant currency basis |
| We're also -- as we said during the prepared remarks, we're expecting for OpEx growth to slow during the second half |
| And operating income was down 5.9% on an as-reported basis, but up 7.3% on a constant currency basis |
| Revenue was down 0.2% on an as-reported basis, but up 11.9% on a constant currency basis |
| And I think everyone in the industry recognizes that the requirements and the expectations for distributors are becoming even more profound, if you look at the drug security and pedigree changes that are coming into place, the high inventory demands, a much more difficult environment in terms of interest rates |
| The as-reported decline reflects the divestiture of Profarma Specialty and unfavorable foreign exchange rates compared to the prior year quarter |
| Healthcare Solutions segment and offset by a slight decline in our International Healthcare Solutions segment, which was negatively impacted by foreign exchange rates and the divestiture of Profarma Specialty in June 2022 |
| Finally, we now expect weighted average diluted share count to be approximately 205 million shares, down from our prior expectation of approximately 206 million shares, due to lower-than-anticipated dilution to date |
| So I don't have a tremendous amount of concern on any of these themes |
| There's been a lot of manufacturer pullback in the 340B space |
| We're only getting smarter |
| On the biotech and the funding, our business gets really impacted by long-term trends |
| Our diluted share count was 204.3 million shares, a 3.6% decrease compared to the second quarter of fiscal 2022, driven by share repurchases we completed over the last 12 months |
Please consider a small donation if you think this website provides you with relevant information